ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987;23(6): 667-675. 117. Bratt G, T rnebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmaco- kinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986;42(5):613-620. 118. Briant L, Caranobe C, Saivin S, et al. Unfractionated hep- arin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost. 1989;61(3):348-353. 119. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmaco- kinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28(7):609-618. 120. M tzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 1987;57(1):97-101. 121. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688-698. 85. Cuker A, Ptashkin B, Konkle BA, et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial throm- boplastin time. J Thromb Haemost. 2009;7(1):80-86. 86. Anand SS, Brimble S, Ginsberg JS. Management of iliofem- oral thrombosis in a pregnant patient with heparin resis- tance. Arch Intern Med. 1997;157(7):815-816. 87. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev. 1994;46(1):89-109. 88. Levine MN, Hirsh J, Gent M, et al. A randomized trial com- paring activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49-56. 89. 